Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC
Initial breath analysis predicted individual treatment response to anti-PD-1 therapy at 3 months.
Non-Small Cell Lung Cancer
Antibiotic Use May Affect Lung Cancer Survival When Treated With Pembrolizumab
In patients with naïve advanced NSCLC and high PD-LI expression who are treated with pembrolizumab, the use of IV antibiotics may negatively impact progression free survival and overall survival.
First-Line Pembrolizumab Effective in Advanced NSCLC, According to 3-Year Follow-Up Data
First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared with chemotherapy.
Do BMI, Age Affect Response to Immune Checkpoint Inhibitors in NSCLC?
Obesity and age do not appear to influence the survival of patients with NSCLC treated with programmed death receptor-1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors.
Nivolumab vs Docetaxel: 5-Year Outcomes in Patients With Advanced NSCLC
Treatment with nivolumab was associated with a 5-fold increase in overall survival compared with chemotherapy, in patients with previously treated non-small cell lung cancer.
Factors Underlying Ethnic Differences in NSCLC Treatment Toxicity, Response
There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.
Adding Adoptive Immunotherapy to Chemotherapy May Improve Survival in NSCLC
Autologous activated killer T cells and dendritic cells from regional lymph nodes were infused with or without chemotherapy in the adjuvant setting.
Comparative Effectiveness, Safety of First-Line Chemotherapy Regimens in Advanced NSCLC
There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.
Addition of Surgical Resection in Stage IV NSCLC May Improve Survival
In select patients with stage IV non-small cell lung cancer, the addition of surgical resection or external beam radiotherapy/thermal ablation of the primary tumor site to systemic therapy may result in improved survival.
Promising Early Results for a “Chemo-Free” Frontline Combo Regimen in Advanced NSCLC
Treatment-related adverse effects of the sintilimab-anlotinib combination regimen included hand-foot syndrome and hyponatremia.
Next post in Lung Cancer
